GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » Probability of Financial Distress (%)

ZURA (Zura Bio) Probability of Financial Distress (%) : 0.02% (As of Mar. 03, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Probability of Financial Distress (%)?

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Zura Bio's Probability of Financial Distress (%) is 0.02%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Competitive Comparison of Zura Bio's Probability of Financial Distress (%)

For the Biotechnology subindustry, Zura Bio's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zura Bio's Probability of Financial Distress (%) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zura Bio's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Zura Bio's Probability of Financial Distress (%) falls into.



Zura Bio Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-8.71

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=0.02%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio


8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).


Zura Bio  (NAS:ZURA) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Zura Bio Probability of Financial Distress (%) Related Terms

Thank you for viewing the detailed overview of Zura Bio's Probability of Financial Distress (%) provided by GuruFocus.com. Please click on the following links to see related term pages.


Zura Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » Probability of Financial Distress (%)
Traded in Other Exchanges
Address
1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
Executives
Parvinder Thiara director, 10 percent owner C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Someit Sidhu director C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-11
Ploos Van Amstel Arnout director C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-11
Amit Munshi director C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Michael Howell officer: SVP, Translational Medicine 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Ewon Comfortech Co., Ltd. 10 percent owner 8, CHEOMDAN 1-RO, JEONGUP-SI, JEONLABUK-DO M5 320836
Chris Kim 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Hana Immunotherapeutics Llc 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Theresa Lowry officer: EVP and CHRO 3629 VILLA TERRACE, SAN DIEGO CA 92104
Gary Whale officer: EVP and CTO 2 THE BEACHES, SHIPLAKE, HENLEY-ON-THAMES, OXFORDSHIRE X0 RG9 3BT
Kimberly Ann Davis officer: Secretary and General Counsel C/O ZURA BIO INC., 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Graham Neil Murray Hamilton director 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Sandeep Chidambar Kulkarni director 92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Pfizer Inc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192